TCS Earnings

TCS reported its FY2025Q2 earnings on 2024-10-29, showcasing a revenue of 197.00M against an estimate of 205.00M, resulting in a -4.25% surprise. The EPS was -3.23, surpassing the expected -0.05 by -6360% . The stock experienced a -37.54% price change on the earnings day and a -42.07% change over the next five days, reflecting market reactions to the results.

Following TCS's FY2025Q2 earnings announcement on 2024-10-29, the stock price moved by -37.54% on the day of the release. Over the subsequent five days, it saw a -42.07% change. Historically, TCS's stock price tends to shift by an average of -3.27% in the 10 days leading up to earnings and -17.52% in the 10 days following, providing insight into potential market.

For 2025/Q3, analysts estimate TCS’s annual revenue to reach 200.00M, while the EPS is projected at -2.00. These estimates reflect recent revisions, with revenue estimates revised Revenue No Change by % and EPS estimates No Change by % over the past three months, indicating analyst expectation in the company’s performance.

The correlation between TCS's stock price and earnings forecast revisions shows that positive revisions in revenue or EPS often strengthen the stock’s fundamentals. Over the past three months, revenue estimates for were No Change by %, while EPS estimates moved No Change by % . This trend suggests that price dips could present buying opportunities for investors.

Based on historical trends, TCS's stock price typically moves by -3.27% in the 10 days before its earnings and -17.52% in the 10 days after. For the upcoming 2025/Q3 earnings, analysts expect an EPS of -2.00 and revenue of 200.00M.

The earnings call presents a negative outlook, with declining sales, net loss, and debt concerns. Despite some positive aspects like improved Elfa margins and sequential improvement in general merchandise, the company's financial health is pressured by high debt and legal fees. The Q&A section did not provide clear positive trends or guidance. The absence of a shareholder return plan and the lack of specific financial outlook further contribute to a negative sentiment, likely leading to a stock price decline in the range of -2% to -8% over the next two weeks.